Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cell Division Cycle 7 Related Protein Kise (CDC7 or EC 2.7.11.1) - Overview
Cell Division Cycle 7 Related Protein Kise (CDC7 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cell Division Cycle 7 Related Protein Kise (CDC7 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cell Division Cycle 7 Related Protein Kise (CDC7 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Car Biosciences Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Eli Lilly and Co
Lin Bioscience Inc
Millennium Pharmaceuticals Inc
Schrodinger Inc
Takeda Pharmaceutical Co Ltd
Zai Lab Ltd
Cell Division Cycle 7 Related Protein Kise (CDC7 or EC 2.7.11.1) - Drug Profiles
AS-0141 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LBS-007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3143921 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SDGR-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
simurosertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
simurosertib - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CDC7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CDc7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
TQB-3824 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cell Division Cycle 7 Related Protein Kise (CDC7 or EC 2.7.11.1) - Dormant Products
Cell Division Cycle 7 Related Protein Kise (CDC7 or EC 2.7.11.1) - Discontinued Products
Cell Division Cycle 7 Related Protein Kise (CDC7 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 03, 2022: Schrodinger to present new preclinical data from its CDC7 inhibitor program at American Society Of Hematology 2022 Annual Meeting
Mar 08, 2022: Schr?dinger to present new preclinical data from its Wee1 inhibitor program at AACR Annual Meeting 2022
Apr 12, 2021: Schr?dinger reports preclinical data on novel, selective CDC7 inhibitors presented at American Association for Cancer Research Annual Meeting
Mar 30, 2021: Schr?dinger to host webcast in conjunction with presentation of preclinical data for its CDC7 program at virtual AACR annual meeting
Mar 10, 2021: Schrodinger announces preclinical data for CDC7 program to be presented at AACR Virtual Annual Meeting 2021
Apr 03, 2019: Sierra reports late-breaking SRA141 preclinical data in poster at AACR 2019
Feb 27, 2019: Sierra Oncology announces late-breaking poster presentation at AACR 2019 for SRA141 preclinical data
Nov 13, 2018: Sierra Oncology reports SRA141 preclinical efficacy at EORTC-NCI-AACR symposium
Nov 09, 2018: Successful Completion of IND filing with FDA for SRA141
Apr 24, 2018: Lin BioScience Announces FDA Orphan Drug Desigtion for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Feb 27, 2018: Sierra Oncology Provides Update on SRA141
Feb 06, 2018: Sierra Oncology to host program update on SRA141 on February 27th in New York
Aug 23, 2017: Cancer Research UK launches trial to test new drug in patients with advanced cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Carna Biosciences Inc, 2022
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Lin Bioscience Inc, 2022
Pipeline by Millennium Pharmaceuticals Inc, 2022
Pipeline by Schrodinger Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Zai Lab Ltd, 2022
Dormant Projects, 2022
Discontinued Products, 2022